Differential role of cannabinoids in the pathogenesis of skin cancer.

AIM Cannabinoids (CB) like ∆(9)-tetrahydrocannabinol (THC) can induce cancer cell apoptosis and inhibit angiogenesis. However, the use of cannabinoids for the treatment of malignant diseases is discussed controversially because of their immunomodulatory effects which can suppress anti-tumor immunity. Here we investigated the role of exogenous and endogenous cannabinoids in mouse skin cancer. MAIN METHODS First we examined the effect of THC, which binds to CB receptors (CB1, CB2), on the growth of the mouse melanoma cell lines B16 and HCmel12 in vitro and in vivo in wild type (WT) and CB1/CB2-receptor deficient mice (Cnr1/2(-/-)). Next we evaluated the role of the endogenous cannabinoid system by studying the growth of chemically induced melanomas, fibrosarcoma and papillomas in WT and Cnr1/2(-/-) mice. KEY FINDINGS THC significantly inhibited tumor growth of transplanted HCmel12 melanomas in a CB receptor-dependent manner in vivo through antagonistic effects on its characteristic pro-inflammatory microenvironment. Chemically induced skin tumors developed in a similar manner in Cnr1/2(-/-) mice when compared to WT mice. SIGNIFICANCE Our results confirm the value of exogenous cannabinoids for the treatment of melanoma but do not support a role for the endogenous cannabinoid system in the pathogenesis of skin cancer.

[1]  D. Tormo,et al.  Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. , 2006, Cancer research.

[2]  M. Piris,et al.  The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. , 2006, Cancer cell.

[3]  M. Nagarkatti,et al.  Activation through Cannabinoid Receptors 1 and 2 on Dendritic Cells Triggers NF-κB-Dependent Apoptosis: Novel Role for Endogenous and Exogenous Cannabinoids in Immunoregulation1 , 2004, The Journal of Immunology.

[4]  S. Werner,et al.  Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System , 2007, Science.

[5]  M. Bifulco,et al.  Endocannabinoid system modulation in cancer biology and therapy. , 2009, Pharmacological research.

[6]  M. Eder,et al.  CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity , 2003, Science.

[7]  T. Tüting,et al.  Cannabinoid 1 receptors in keratinocytes attenuate fluorescein isothiocyanate‐induced mouse atopic‐like dermatitis , 2014, Experimental dermatology.

[8]  C. Newton,et al.  Cannabinoids and the immune system. , 2001, Pain research & management.

[9]  I. Díaz-Laviada,et al.  Δ9‐Tetrahydrocannabinol induces apoptosis in human prostate PC‐3 cells via a receptor‐independent mechanism , 1999, FEBS letters.

[10]  M. Barbacid,et al.  Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation. , 2006, The American journal of pathology.

[11]  M. Nagarkatti,et al.  Δ-9-Tetrahydrocannabinol Enhances Breast Cancer Growth and Metastasis by Suppression of the Antitumor Immune Response1 , 2005, The Journal of Immunology.

[12]  N. Kaminski,et al.  Cannabinoids inhibit the activation of ERK MAPK in PMA/Io-stimulated mouse splenocytes. , 2003, International immunopharmacology.

[13]  M. Herkenham,et al.  Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Planas,et al.  The FASEB Journal express article 10.1096/fj.02-0795fje. Published online January 2, 2003. Inhibition of tumor angiogenesis by cannabinoids , 2022 .

[15]  Thomas W. Klein,et al.  Cannabinoid receptors and T helper cells , 2004, Journal of Neuroimmunology.

[16]  M. Vitale,et al.  Anandamide inhibits adhesion and migration of breast cancer cells. , 2006, Experimental cell research.

[17]  T. Tüting,et al.  Anti‐inflammatory activity of topical THC in DNFB‐mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors , 2013, Allergy.

[18]  F. Mach,et al.  Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice , 2005, Nature.

[19]  B. Cravatt,et al.  The endogenous cannabinoid system protects against colonic inflammation. , 2004, The Journal of clinical investigation.

[20]  V. Marzo,et al.  A new strategy to block tumor growth by inhibiting endocannabinoid inactivation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  V. Di Marzo,et al.  Endocannabinoid overactivity and intestinal inflammation , 2006, Gut.

[22]  Li Zhu,et al.  Δ-9-Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway1 , 2000, The Journal of Immunology.

[23]  M. Nagarkatti,et al.  Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. , 2005, Journal of immunology.

[24]  M. Malumbres,et al.  Cannabinoid receptors as novel targets for the treatment of melanoma , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  Cristina Blázquez,et al.  Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. , 2003, The Journal of clinical investigation.

[26]  Thomas de Quincey.  [C] , 2000, The Works of Thomas De Quincey, Vol. 1: Writings, 1799–1820.

[27]  J. Landsberg,et al.  Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation , 2012, Nature.

[28]  Duo Zheng,et al.  The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. , 2008, Cancer research.

[29]  M. Nagarkatti,et al.  Δ9-Tetrahydrocannabinol-Induced Apoptosis in the Thymus and Spleen as a Mechanism of Immunosuppression in Vitro and in Vivo , 2002, Journal of Pharmacology and Experimental Therapeutics.

[30]  P. Massi,et al.  Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity. , 2000, European journal of pharmacology.

[31]  M. Cortés,et al.  Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation , 2000, Nature Medicine.

[32]  Gebräuchliche Fertigarzneimittel,et al.  V , 1893, Therapielexikon Neurologie.

[33]  D. Schadendorf,et al.  Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma , 2014, Nature.

[34]  P. Massi,et al.  Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor‐independent mechanism , 2005, British journal of pharmacology.

[35]  H. Friedman,et al.  Contrasting effect of delta-9-tetrahydrocannabinol on IL-2 activity in spleen and lymph node cells of mice of different ages. , 1993, Life sciences.

[36]  T. Bonner,et al.  Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. , 2000, European journal of pharmacology.

[37]  M. Neurath,et al.  VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer , 2010, The Journal of experimental medicine.

[38]  M. Guzmán,et al.  Cannabinoids: potential anticancer agents , 2003, Nature Reviews Cancer.

[39]  A. Ullrich,et al.  Cannabinoids Induce Cancer Cell Proliferation via Tumor Necrosis Factor α-Converting Enzyme (TACE/ADAM17)-Mediated Transactivation of the Epidermal Growth Factor Receptor , 2004, Cancer Research.

[40]  S. Dey,et al.  Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. , 2008, Cancer research.